Physician profile
Emily Neri
NPI 1366602419
$13,006.48
in general payments reported to CMS, 2019-2025
29 companies · $8,862 in 2025
The $8,862 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $234 · 2021: $440 · 2022: $461 · 2023: $752 · 2024: $861 · 2025: $8,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,000 · Food and Beverage: $2,376 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,000.00 |
| Food and Beverage | $2,376.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtual Incision Corporation | $8,056.95 | 2025 | Mira |
| Coloplast Corp | $1,127.81 | 2019-2021 | |
| Abbvie INC. | $887.57 | 2019-2025 | |
| Astellas Pharma US INC | $662.14 | 2020-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $301.98 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $281.55 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $264.97 | 2019-2025 | |
| Daiichi Sankyo INC. | $138.09 | 2020-2023 | Injectafer |
| Exeltis, USA INC. | $130.68 | 2021-2025 | Slynd |
| Organon LLC | $125.80 | 2022-2025 | Nexplanon |
| Biogen, INC. | $117.68 | 2024-2025 | Zurzuvae |
| Meditrina | $107.25 | 2021 | |
| Coopersurgical, INC. | $103.27 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $93.86 | 2021-2023 | |
| Hologic Sales and Service, LLC | $93.43 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $91.55 | 2019-2023 | Gardasil 9 |
| Conmed Corporation | $79.52 | 2024 | |
| Myovant Sciences INC. | $74.16 | 2022 | |
| Allergan, INC. | $51.93 | 2019-2020 | |
| Therapeuticsmd, INC. | $45.91 | 2020-2021 | |
| Boston Scientific Corporation | $31.71 | 2019-2024 | Advantage System |
| Ethicon US, LLC | $29.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.10 | 2022 | |
| Myriad Women'S Health, INC. | $21.20 | 2023 | Myrisk |
| Scynexis, INC. | $13.70 | 2022 | |
| Minerva Surgical, INC | $13.50 | 2024 | |
| Evofem Biosciences, INC. | $13.03 | 2022 | |
| Exact Sciences Corporation | $13.02 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Neri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.